# EDGAR Filing Document

**Accession Number:** 0001958086
**File Stem:** 0001193125-26-198109
**Filing Date:** 2026-5
**Character Count:** 118193
**Document Hash:** 64170bf83b1782409c21b963c5f28016
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-198109.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001193125-26-198109

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 67

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260501

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Core Laboratories Inc. /DE/
- **CENTRAL INDEX KEY:** 0001958086
- **STANDARD INDUSTRIAL CLASSIFICATION:** OIL, GAS FIELD SERVICES, NBC [1389]
- **ORGANIZATION NAME:** 01 Energy & Transportation
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41695
- **FILM NUMBER:** 26927852

**BUSINESS ADDRESS:**
- **STREET 1:** 6316 WINDFERN ROAD
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77040
- **BUSINESS PHONE:** 713-328-2673

**MAIL ADDRESS:**
- **STREET 1:** 6316 WINDFERN ROAD
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77040

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Core Laboratories Luxembourg S.A.
- **DATE OF NAME CHANGE:** 20221213

?xml version='1.0' encoding='ASCII'? 10-Q

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended** **March 31,** 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ______________

Commission File Number: 001-41695

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| Delaware | 98-1164194 |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer Identification No.) |
| 6316 Windfern Road |  |
| Houston**,** TX | 77040 |
| (Address of principal executive offices) | (Zip Code) |

---

**(**713**)** 328-2673

(Registrant's telephone number, including area code)

**None**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock (par value $0.01)<br> CLB | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ <br>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock of the registrant, par value $0.01 per share, outstanding at April 24, 2026 was 46,096,682.

------

**CORE LABORATORIES INC.**

**FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026**

**INDEX**

**PART I - FINANCIAL INFORMATION**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [<u>Item 1.</u>](#item_1_financial_statements) | [<u>Financial Statements</u>](#item_1_financial_statements) |  |
|  | [<u>Consolidated Balance Sheets at March 31, 2026 (Unaudited) and December 31, 2025</u>](#consolidated_balance_sheets) | 3 |
|  | [<u>Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025</u>](#consolidated_statements_operation3mths)[<u>(Unaudited)</u>](#consolidated_statements_operation3mths) | 4 |
|  | [<u>Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2026 and 2025 (</u>](#consolidated_statements_comprehensive_in)[<u>Unaudited)</u>](#consolidated_statements_comprehensive_in) | 5 |
|  | [<u>Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2026 and 2025</u>](#consolidated_statements_equity)[<u>(Unaudited)</u>](#consolidated_statements_equity) | 6 |
|  | [<u>Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025</u>](#consolidated_statements_cash_flows)[<u>(Unaudited)</u>](#consolidated_statements_cash_flows) | 8 |
|  | [<u>Notes to the Interim Consolidated Financial Statements (Unaudited)</u>](#notes_to_unaudited_consolidated_interim_) | 9 |
| [<u>Item 2.</u>](#item_2_managements_discussion_analysis_f) | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 19 |
| [<u>Item 3.</u>](#item_3__quantitative_and_qualitative_dis) | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3__quantitative_and_qualitative_dis) | 30 |
| [<u>Item 4.</u>](#item_4__controls_and_procedures) | [<u>Controls and Procedures</u>](#item_4__controls_and_procedures) | 30 |
| **PART II - OTHER INFORMATION** | **PART II - OTHER INFORMATION** | **PART II - OTHER INFORMATION** |
| [<u>Item 1.</u>](#item_1_legal_proceedings) | [<u>Legal Proceedings</u>](#item_1_legal_proceedings) | 31 |
| [<u>Item 1A.</u>](#item_1a_risk_factors) | [<u>Risk Factors</u>](#item_1a_risk_factors) | 31 |
| [<u>Item 2.</u>](#item_2_unregistered_sales_equity_securit) | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 31 |
| [<u>Item 5.</u>](#item_5_other_info) | [<u>Other Information</u>](#item_5_other_info) | 31 |
| [<u>Item 6.</u>](#item_6_exhibits) | [<u>Exhibits</u>](#item_6_exhibits) | 32 |
|  | [<u>Signature</u>](#signature) | 33 |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**CORE LABORATORIES INC.**

**CONSOLIDATED BALANCE SHEETS**

**(In thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
|  | **(Unaudited)** |  |
| **ASSETS** |  |  |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $22819 | $22702 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for credit losses <br>&nbsp;&nbsp;&nbsp;&nbsp; of $6,488 and $6,317 at 2026 and 2025, respectively | 108277 | 113528 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 57784 | 54496 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 11356 | 9734 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable | 6917 | 7270 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 7218 | 6935 |
| TOTAL CURRENT ASSETS | 214371 | 214665 |
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation <br>&nbsp;&nbsp;&nbsp;&nbsp; of $319,112 and $320,707 at 2026 and 2025, respectively | 99985 | 99447 |
| RIGHT OF USE ASSETS | 54708 | 54346 |
| INTANGIBLES, net of accumulated amortization and impairment <br>&nbsp;&nbsp;&nbsp;&nbsp; of $19,739 and $19,531 at 2026 and 2025, respectively | 6893 | 7118 |
| GOODWILL | 105796 | 105789 |
| DEFERRED TAX ASSETS, net | 71296 | 67381 |
| OTHER ASSETS | 34679 | 35264 |
| TOTAL ASSETS | $587728 | $584010 |
| **LIABILITIES AND EQUITY** |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $39982 | $37275 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and related costs | 22295 | 26525 |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes other than payroll and income | 4065 | 4272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unearned revenues | 4708 | 5552 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 12097 | 11456 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 4214 | 4255 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 17373 | 16680 |
| TOTAL CURRENT LIABILITIES | 104734 | 106015 |
| LONG-TERM DEBT, net | 114460 | 110255 |
| LONG-TERM OPERATING LEASE LIABILITIES | 41285 | 42309 |
| DEFERRED COMPENSATION | 28165 | 29381 |
| DEFERRED TAX LIABILITIES, net | 8073 | 7995 |
| OTHER LONG-TERM LIABILITIES | 15867 | 15847 |
| COMMITMENTS AND CONTINGENCIES |  |  |
| EQUITY: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preference stock, 6,000,000 shares authorized, $0.01 par value; <br>none issued or outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, 200,000,000 shares authorized, $0.01 par value,<br> 46,966,868 issued and 46,048,268 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025 | 470 | 470 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 115221 | 110245 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 171413 | 172662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (5754) | (5806) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock (at cost), 918,600 and 871,489 shares at 2026 and 2025, respectively | (12464) | (11585) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Core Laboratories Inc. shareholders' equity | 268886 | 265986 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-controlling interest | 6258 | 6222 |
| TOTAL EQUITY | 275144 | 272208 |
| TOTAL LIABILITIES AND EQUITY | $587728 | $584010 |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share data)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(Unaudited)** | **(Unaudited)** |
| REVENUE: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | $94252 | $95091 |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales | 27545 | 28494 |
| Total revenue | 121797 | 123585 |
| OPERATING EXPENSES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services, exclusive of depreciation expense shown below | 76115 | 72980 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product sales, exclusive of depreciation expense shown below | 25958 | 26489 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense, exclusive of depreciation expense shown below | 14718 | 13647 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 3556 | 3593 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 208 | 124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (645) | 2335 |
| OPERATING INCOME | 1887 | 4417 |
| Interest expense | 2891 | 2602 |
| Income (loss) before income taxes | (1004) | 1815 |
| Income tax expense (benefit) | (251) | 1746 |
| Net income (loss) | (753) | 69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to non-controlling interest | 36 | 223 |
| Net income (loss) attributable to Core Laboratories Inc. | $(789) | $(154) |
| EARNINGS PER SHARE INFORMATION: |  |  |
| Basic earnings (loss) per share | $(0.02) | $— |
| Basic earnings (loss) per share attributable to Core Laboratories Inc. | $(0.02) | $— |
| Diluted earnings (loss) per share | $(0.02) | $— |
| Diluted earnings (loss) per share attributable to Core Laboratories Inc. | $(0.02) | $— |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |  |  |
| Basic | 46073 | 46773 |
| Assuming dilution | 46073 | 46773 |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(Unaudited)** | **(Unaudited)** |
| Net income (loss) | $(753) | $69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate swaps: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap amount reclassified to net income | (6) | (220) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit on interest rate swaps reclassified to net income | 1 | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total interest rate swaps | (5) | (174) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement benefit plans: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of actuarial gain reclassified to net income | 77 | 77 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense on pension and other postretirement benefit plans reclassified to net income | (20) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total pension and other postretirement benefit plans | 57 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | 52 | (117) |
| Comprehensive loss | (701) | (48) |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income attributable to non-controlling interest | 36 | 223 |
| Comprehensive loss attributable to Core Laboratories Inc. | $(737) | $(271) |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

**(In thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(Unaudited)** | **(Unaudited)** |
| **Common Stock** |  |  |
| Balance at Beginning of Period | $470 | $470 |
| Balance at End of Period | $470 | $470 |
| **Additional Paid-In Capital** |  |  |
| Balance at Beginning of Period | $110245 | $109547 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 4976 | 4027 |
| Balance at End of Period | $115221 | $113574 |
| **Retained Earnings** |  |  |
| Balance at Beginning of Period | $172662 | $144862 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | (460) | (469) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to Core Laboratories Inc. | (789) | (154) |
| Balance at End of Period | $171413 | $144239 |
| **Accumulated Other Comprehensive Income (Loss)** |  |  |
| Balance at Beginning of Period | $(5806) | $(5769) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swaps, net of income taxes | (5) | (174) |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement benefit plans, net of income taxes | 57 | 57 |
| Balance at End of Period | $(5754) | $(5886) |
| **Treasury Stock** |  |  |
| Balance at Beginning of Period | $(11585) | $(2537) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 56 | 132 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (935) | (2022) |
| Balance at End of Period | $(12464) | $(4427) |
| **Non-Controlling Interest** |  |  |
| Balance at Beginning of Period | $6222 | $5745 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to non-controlling interest | 36 | 223 |
| Balance at End of Period | $6258 | $5968 |
| **Total Equity** |  |  |
| Balance at Beginning of Period | $272208 | $252318 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 5032 | 4159 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | (460) | (469) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | (753) | 69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swaps, net of income taxes | (5) | (174) |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement benefit plans, net of income taxes | 57 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (935) | (2022) |
| Balance at End of Period | $275144 | $253938 |
| **Cash Dividends per Share** | $**0.01** | $**0.01** |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Continued)**

**(In thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(Unaudited)** | **(Unaudited)** |
| **Common Stock - Number of shares issued** |  |  |
| Balance at Beginning of Period | 46966868 | 46966868 |
| Balance at End of Period | 46966868 | 46966868 |
| **Treasury Stock - Number of shares** |  |  |
| Balance at Beginning of Period | (871489) | (140048) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 4670 | 6970 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (51781) | (131598) |
| Balance at End of Period | (918600) | (264676) |
| **Common Stock - Number of shares outstanding** |  |  |
| Balance at Beginning of Period | 46095379 | 46826820 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 4670 | 6970 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (51781) | (131598) |
| Balance at End of Period | 46048268 | 46702192 |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(Unaudited)** | **(Unaudited)** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Net income (loss) | $(753) | $69 |
| &nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by operating activities: | &nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 5032 | 4159 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3764 | 3717 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets write-down | 180 | 34 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory write-off and obsolescence | 168 | 643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net provision for credit losses | 241 | 668 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in value of life insurance policies | 513 | 779 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (3719) | (1817) |
| &nbsp;&nbsp;&nbsp;&nbsp;Realization of pension obligation | 47 | 45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash items | (730) | 872 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 5010 | (6606) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (3456) | (272) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (1551) | 1391 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (7) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 2847 | 2971 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (845) | 617 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unearned revenues | (844) | 440 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | (1932) | (1053) |
| Net cash provided by operating activities | 3965 | 6660 |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Capital expenditures - operations | (3448) | (2785) |
| &nbsp;&nbsp;Capital expenditures - rebuilding of Aberdeen facility | (1443) | (794) |
| &nbsp;&nbsp;Proceeds from insurance recovery - Aberdeen facility |  | 3121 |
| &nbsp;&nbsp;Proceeds from sale of assets | 1491 | 1230 |
| &nbsp;&nbsp;Patents and other intangibles | 9 |  |
| Net cash provided by (used in) investing activities | (3391) | 772 |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Repayment of long-term debt | (62000) | (15000) |
| &nbsp;&nbsp;Proceeds from long-term debt | 66000 | 13000 |
| &nbsp;&nbsp;Dividends paid | (460) | (469) |
| &nbsp;&nbsp;Repurchase of common stock | (3997) | (2022) |
| &nbsp;&nbsp;Other financing activities |  | 9 |
| Net cash used in financing activities | (457) | (4482) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 117 | 2950 |
| CASH AND CASH EQUIVALENTS, beginning of period | 22702 | 19157 |
| CASH AND CASH EQUIVALENTS, end of period | $22819 | $22107 |
| Supplemental disclosures of cash flow information: |  |  |
| &nbsp;&nbsp;Cash payments for interest | $2875 | $2260 |
| &nbsp;&nbsp;Cash payments (net of refunds) for income taxes | $2971 | $1015 |
| Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;Capital expenditures incurred but not paid for as of the end of the period | $1482 | $1990 |

---

The accompanying notes are an integral part of these interim consolidated financial statements.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**1. DESCRIPTION OF BUSINESS** 

References to "Core Lab", "Core Laboratories", the "Company", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q ("Quarterly Report") and relate collectively to Core Laboratories Inc. and its consolidated subsidiaries.

We operate our business in two segments: (1) Reservoir Description and (2) Production Enhancement. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of the types of services and products offered by these operating segments, see Note 15 - S*egment Reporting*.

**2. SIGNIFICANT ACCOUNTING POLICIES UPDATE**

***Basis of Presentation and Principles of Consolidation***

The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements and notes thereto included in Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025, including Note 2 - *Summary of Significant Accounting Policies.* Core Laboratories Inc.'s balance sheet information for the year ended December 31, 2025, was derived from the 2025 audited consolidated financial statements. There have been no changes to the accounting policies during the three months ended March 31, 2026, except as noted below.

Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation.

In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three months ended March 31, 2026, may not necessarily be indicative of the results that may be expected for the year ending December 31, 2026.

Certain reclassifications were made to prior period amounts included in this Quarterly Report on Form 10-Q in order to conform to the current period presentations. Refer to Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025, Note 2 - *Summary of Significant Accounting Policies - Prior Period Immaterial Corrections*. Specifically, the Company has made adjustments to previously reported beginning retained earnings and total assets for the three months ended March 31, 2025. These reclassifications had no impact on the reported net income or cash flows for the three months ended March 31, 2025.

***Property, Plant and Equipment***

We review our long-lived assets ("LLA") for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions.

[<u>Return to Index</u>](#index)

------

We have performed assessments for LLA located in regions impacted by the Middle East and Russia/Ukraine geopolitical conflicts and no triggering events have been identified to indicate that their net book value may not be recoverable as of March 31, 2026.

***Recent Accounting Pronouncements*** 

*Pronouncements Adopted in 2026*

In July 2025, FASB issued ASU 2025-05 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which allows public business entities to apply a practical expedient when estimating expected credit losses that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendment is effective for annual and interim periods beginning after December 15, 2025. We adopted the guidance during the three months ended March 31, 2026. The Company has elected to apply the practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. When an account is determined to be uncollectible, we charge the receivable to our allowance for credit losses.

*Issued But Not Yet Effective* 

In November 2024, FASB issued ASU 2024-03 Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) to improve disclosures about a public business entity's expenses, by providing more detailed information about the types of expenses in commonly presented expense captions. As amended by ASU 2025-01 issued in January 2025, the amendment is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendment may be applied prospectively or retrospectively. Upon adoption, our disclosures regarding expenses will be expanded.

In December 2025, FASB issued ASU 2025-11—Interim Reporting (Topic 270): Narrow-Scope Improvements to clarify the applicability of Topic 270, including types of interim reporting and the form and content of interim financial statements. It also provides a comprehensive list of required interim disclosures and requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendment is effective for interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. We do not expect the update to have an effect on our interim reporting.

**3. ACQUISITIONS AND DIVESTITURES**

We had no significant business acquisitions or divestitures during the three months ended March 31, 2026 and 2025.

**4. INVENTORIES**

Inventories consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Finished goods | $27201 | $24962 |
| Parts and materials | 27752 | 26932 |
| Work in progress | 2831 | 2602 |
| &nbsp;&nbsp; Total inventories | $57784 | $54496 |

---

We include freight costs incurred for shipping inventory to our clients in the cost of product sales caption in the accompanying consolidated statements of operations.

[<u>Return to Index</u>](#index)

------

**5. LEASES**

Our operating leases primarily consist of offices and lab space, machinery, equipment, and vehicles. We terminated certain leases in the U.S. and other international locations during the three months ending March 31, 2026 and 2025. See Note 12 - *Other (Income) Expense, net* for additional information regarding lease termination costs.

The components of lease expense and other information are as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **Consolidated Statements of Operations:** |  |  |
| Operating lease expense | $4475 | $4178 |
| Short-term lease expense | 411 | 489 |
| Variable lease expense | 479 | 481 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total lease expense | $5365 | $5148 |
| **Consolidated Statements of Cash Flows:** |  |  |
| &nbsp;&nbsp; Operating cash flows - operating leases payments | $4431 | $4206 |
| &nbsp;&nbsp; Right of use assets obtained in exchange for<br>operating lease liabilities | $4354 | $4155 |
| **Other information:** |  |  |
| &nbsp;&nbsp; Weighted-average remaining lease term - operating leases | 7.72 years | 8.38 years |
| &nbsp;&nbsp; Weighted-average discount rate - operating leases | 5.42% | 5.46% |

---

Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands):

---

| | |
|:---|:---|
|  | **March 31, 2026** |
|  | **Operating Leases** |
| Remainder of 2026 | $12703 |
| 2027 | 11257 |
| 2028 | 8810 |
| 2029 | 6145 |
| 2030 | 4320 |
| Thereafter | 22904 |
| &nbsp;&nbsp;Total undiscounted lease payments | 66139 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Imputed interest | (12757) |
| &nbsp;&nbsp;Total operating lease liabilities | $53382 |

---

**6. LONG-TERM DEBT, NET**

We have no finance lease obligations. Debt is summarized in the following table (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Interest Rate** | **Maturity Date** | **March 31,<br>2026** | **December 31,<br>2025** |
| Credit Facility - Revolving Loan | Variable | July 22, 2029 | $2000 | $3000 |
| Credit Facility - Delayed Draw Term Loan | Variable | July 22, 2029 | 50000 |  |
| 2021 Senior Notes Series A <sup>(1)</sup> | 4.09% | January 12, 2026 |  | 45000 |
| 2021 Senior Notes Series B <sup>(1)</sup> | 4.38% | January 12, 2028 | 15000 | 15000 |
| 2023 Senior Notes Series A <sup>(2)</sup> | 7.25% | June 28, 2028 | 25000 | 25000 |
| 2023 Senior Notes Series B <sup>(2)</sup> | 7.50% | June 28, 2030 | 25000 | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt |  |  | 117000 | 113000 |
| Less: Debt issuance costs |  |  | (2540) | (2745) |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, net |  |  | $114460 | $110255 |

---

&nbsp;&nbsp;&nbsp;&nbsp;*(1) Interest is payable semi-annually on June 30 and December 30.*

[<u>Return to Index</u>](#index)

------

&nbsp;&nbsp;&nbsp;&nbsp;*(2) Interest is payable semi-annually on March 28 and September 28.*

On July 22, 2025, we, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. ("CLIH") entered into the Ninth Amended and Restated Credit Agreement (as amended, the "Credit Facility") for an aggregate borrowing commitment of $150.0 million with a $50.0 million "accordion" feature. Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million was made in the form of a delayed draw term loan ("DDTL") on January 12, 2026. The $50.0 million proceeds from the DDTL were primarily used to retire $45.0 million of Senior Notes Series A, which matured on January 12, 2026, see further discussion below. The DDTL is repayable in quarterly installments of $625 thousand beginning June 2026, and prepayments are permitted without penalty. We intend to repay the DDTL using borrowings under our existing long-term credit facility, therefore, we continue to classify this term loan as long-term debt. Any remaining outstanding balances under the revolving credit facility and the DDTL are due at maturity on July 22, 2029, subject to springing maturity dates unless the Company's liquidity equals or exceeds the principal amount of each of the respective senior notes series that remain outstanding on each of the respective springing maturity dates as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)October 14, 2027, if any portion of the Company's 2021 Senior Notes Series B due January 12, 2028, in the aggregate principal amount of $15.0 million, remains outstanding on October 14, 2027, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)March 30, 2028, if any portion of the Company's 2023 Senior Notes Series A due June 28, 2028, in the aggregate principal amount of $25.0 million, remains outstanding on March 30, 2028.

The Credit Facility is secured by first priority interests in (1) substantially all of the tangible and intangible personal property, and equity interest of CLIH and certain of the Company's U.S. and foreign subsidiary companies and (2) instruments evidencing intercompany indebtedness owing to the Company, CLIH and certain of the Company's U.S. and foreign subsidiary companies. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

Under the Credit Facility, the Secured Overnight Financing Rate ("SOFR") plus 2.00% to SOFR plus 3.00% will be applied to outstanding borrowings. The available capacity at any point in time is reduced by outstanding borrowings and outstanding letters of credit which totaled approximately $12.5 million at March 31, 2026, resulting in an available borrowing capacity under the Credit Facility of approximately $85.5 million. In addition to indebtedness under the Credit Facility, we had approximately $6.9 million of outstanding letters of credit and performance guarantees and bonds from other sources as of March 31, 2026.

The Credit Facility and Senior Notes include a cross-default provision, whereby a default under one agreement may trigger a default in the other agreements.

The terms of the Credit Facility and Senior Notes require us to meet certain covenants, including, but not limited to, an interest coverage ratio (calculated as consolidated EBITDA divided by interest expense) and a leverage ratio (calculated as consolidated net indebtedness divided by consolidated EBITDA), where consolidated EBITDA (as defined in each agreement) and interest expense are calculated using the most recent four fiscal quarters. The Credit Facility has more restrictive covenants with a minimum interest coverage ratio of 3.00 to 1.00 and permits a maximum leverage ratio of 2.50 to 1.00. The Credit Facility allows non-cash charges such as impairment of assets, stock compensation and other non-cash charges to be added back in the calculation of consolidated EBITDA. The terms of our Credit Facility also allow us to negotiate in good faith to amend any ratio or requirement to preserve the original intent of the agreement if any change in accounting principles would affect the computation of any financial ratio or covenant of the Credit Facility. In accordance with the terms of the Credit Facility, our leverage ratio is 1.20 and our interest coverage ratio is 7.20, each for the period ended March 31, 2026. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of March 31, 2026.

We, along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions. Series B of the 2021 Senior Notes were issued in 2021 (the "2021 Senior Notes"). Series A and Series B of the 2023 Senior Notes were issued in 2023 (the "2023 Senior Notes"). The 2021 Senior Notes and the 2023 Senior Notes are collectively the "Senior

[<u>Return to Index</u>](#index)

------

Notes". On January 12, 2026, we repaid the 2021 Senior Notes Series A with aggregate principal amount of $45.0 million upon the maturity date with the single draw of $50.0 million from the delayed draw term loan.

See Note 10 - *Derivative Instruments and Hedging Activities* for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our 2023 Senior Notes.

The estimated fair value of total debt at March 31, 2026 and December 31, 2025, approximated the book value of total debt. The fair value was estimated using Level 2 inputs by calculating the sum of the discounted future interest and principal payments through the maturity date.

**7. PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS**

Prior to January 2020, one of our subsidiaries provided a noncontributory defined benefit pension plan covering substantially all of our Dutch employees who were hired prior to 2000 ("Dutch Plan"). This pension benefit was based on years of service and final pay or career average pay, depending on when the employee began participating. The Dutch Plan was curtailed prior to January 2020, and these employees have been moved into the Dutch defined contribution plan. However, the unconditional indexation for this group of participants continues for so long as they remain in active service with the Company.

The components of net periodic pension cost for the Dutch Plan include (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Interest cost | $423 | $347 |
| Expected return on plan assets | (350) | (280) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension cost | $73 | $67 |

---

**8. COMMITMENTS AND CONTINGENCIES**

We have been and may, from time to time, be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. A liability is accrued when a loss is both probable and can be reasonably estimated.

See Note 6 - *Long-term Debt, net* for amounts committed under letters of credit and performance guarantees and bonds.

**9. EQUITY**

***Treasury Stock***

During the three months ended March 31, 2026, we distributed 4,670 shares of treasury stock upon vesting of stock-based awards. During the three months ended March 31, 2026, we repurchased 51,781 shares of our common stock for $0.9 million, of which 1,695 shares valued at $29 thousand were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participant's tax burdens resulting from the issuance of common stock under the plan. Such shares of common stock, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards.

***Dividend Policy***

In March 2026, we paid a quarterly cash dividend of $0.01 per share of common stock. In addition, on April 29, 2026, we declared a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 11, 2026, and payable on June 1, 2026.

[<u>Return to Index</u>](#index)

------

***Accumulated Other Comprehensive Income (Loss)***

Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss | $(5442) | $(5499) |
| Interest rate swaps - net gain (loss) on fair value | (312) | (307) |
| &nbsp;&nbsp;Total accumulated other comprehensive income (loss) | $(5754) | $(5806) |

---

***Retained Earnings***

The beginning balances of retained earnings and total equity for the three months ended March 31, 2025 have been adjusted for certain prior period immaterial corrections. See Note 2 - *Summary of Significant Accounting Policies Update*.

**10. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES**

We are exposed to market risks related to fluctuations in interest rates. To mitigate these risks, we may utilize derivative instruments in the form of interest rate swaps. We do not enter into derivative transactions for speculative purposes.

In March 2021, we entered into a forward interest rate swap agreement and carried the fair value of certain terminated variable-to-fixed swaps into the agreement in a "blend and extend" structured transaction. The purpose of this forward interest rate swap agreement was to fix the underlying risk-free rate, that would be associated with the anticipated issuance of new long-term debt by the Company in future periods. The forward interest rate swap would hedge the risk-free rate on forecasted long-term debt through March 2033. Risk associated with future changes in the 10-year LIBOR interest rates were fixed up to a notional amount of $60.0 million with this instrument. The interest rate swap qualified as a cash flow hedging instrument. The forward interest rate swap agreement was terminated and settled in April 2022. The hedging relationship was highly effective, therefore, the gain on the termination of the forward interest rate swap was included in accumulated other comprehensive income (loss). In June 2023, the Company issued the 2023 Senior Notes with an aggregate principal amount of $50.0 million at fixed interest rates of 7.25% and 7.50%. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the 2023 Senior Notes will preclude cash flow hedging with the LIBOR hedging instrument. The unamortized net loss on this swap included in accumulated other comprehensive income (loss) at March 31, 2026 of $0.3 million will be amortized into interest expense in accordance with the forecasted transactions or the scheduled interest payments on the 2023 Senior Notes and any future debt through March 2033.

The effect of interest rate swaps on the consolidated statements of operations is as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |  |
|  | **March 31,** | **March 31,** |  |
|  | **2026** | **2025** | **Income Statement <br>Classification** |
| **Derivatives designated as hedges:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;5 year interest rate swap | $— | $(12) | Increase (decrease) to interest expense |
| &nbsp;&nbsp;&nbsp;&nbsp;10 year interest rate swap | (6) | (208) | Increase (decrease) to interest expense |
|  | $(6) | $(220) |  |

---

**11. FINANCIAL INSTRUMENTS** 

[<u>Return to Index</u>](#index)

------

The Company's only financial assets and liabilities which are measured at fair value on a recurring basis relate to certain aspects of the Company's benefit plans. We use the market approach to determine the fair value of these assets and liabilities using significant other observable inputs (Level 2) with the assistance of third-party specialists. We do not have any assets or liabilities measured at fair value on a recurring basis using quoted prices in an active market (Level 1) or significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the financial assets and liabilities are recorded in general and administrative expense in the consolidated statements of operations.

The following table summarizes the fair value balances (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurement at** | **Fair Value Measurement at** | **Fair Value Measurement at** |
|  |  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Company owned life insurance policies <sup>(1)</sup> | $26097 | $— | $26097 | $— |
|  | $26097 | $— | $26097 | $— |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation liabilities | $18565 | $— | $18565 | $— |
|  | $18565 | $— | $18565 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurement at** | **Fair Value Measurement at** | **Fair Value Measurement at** |
|  |  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Company owned life insurance policies <sup>(1)</sup> | $26627 | $— | $26627 | $— |
|  | $26627 | $— | $26627 | $— |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation liabilities | $18451 | $— | $18451 | $— |
|  | $18451 | $— | $18451 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.*

**12. OTHER (INCOME) EXPENSE, NET**

The components of other (income) expense, net, are as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Gain on sale of assets | $(1013) | $(6) |
| Results of non-consolidated subsidiaries | 79 | (37) |
| Foreign exchange (gain) loss, net | 380 | 480 |
| Rents and royalties |  | (7) |
| Return on pension assets and other pension costs | (350) | (280) |
| Assets write-down, loss on lease termination and other exit costs | 639 | 707 |
| Severance and other charges |  | 2256 |
| Other, net | (380) | (778) |
| &nbsp;&nbsp;Total other (income) expense, net | $(645) | $2335 |

---

During the three months ended March 31, 2026 and 2025, as a result of our continuous efforts in consolidating and exiting certain facilities in the U.S. and other international locations for operational efficiency, we sold property in Tulsa, Oklahoma for a net gain of $0.9 million. In addition, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease termination and other exit costs of $0.6 million and $0.7 million, respectively.

[<u>Return to Index</u>](#index)

------

Foreign exchange (gain) loss, net for the primary currencies in which we operate and those with a material effect for the period presented is summarized in the following table (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| British Pound | $(64) | $(6) |
| Canadian Dollar | 23 | 46 |
| Euro | (70) | 285 |
| Indonesian Rupiah | 50 | 74 |
| Russian Ruble | 97 | (185) |
| Other currencies, net | 344 | 266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gain) loss, net | $380 | $480 |

---

**13. INCOME TAX EXPENSE (BENEFIT)** 

The Company recorded an income tax benefit of $(0.3) million for the three months ended March 31, 2026 compared to income tax expense of $1.7 million for the three months ended March 31, 2025. The effective tax rate for the three months ended March 31, 2026 and 2025, was 25.0% and 96.2%, respectively . The effective tax rate for the three months ended March 31, 2026, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter. The effective tax rate for the three months ended March 31, 2025, was impacted by approximately $1.4 million of additional tax expense recorded for items discrete to the quarter. These discrete items are primarily associated with the finalization of certain tax jurisdictions' return to provision assessments due to changes in estimates.

**14. EARNINGS (LOSS) PER SHARE**

We compute basic earnings (loss) per share by dividing net income (loss) attributable to Core Laboratories Inc. by the number of weighted average common shares outstanding during the period. Diluted earnings (loss) per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method.

The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings (loss) per share (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Weighted average common shares outstanding - basic | 46073 | 46773 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted shares |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Performance shares |  |  |
| Weighted average common shares outstanding - assuming dilution | 46073 | 46773 |

---

For the three months ended March 31, 2026 and 2025, the number of Core Laboratories Inc. restricted and performance shares of common stock that were excluded from the diluted earnings (loss) per share calculation as their impact would be antidilutive, were as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Restricted shares | 89 | 77 |
| Performance shares | 887 | 730 |

---

[<u>Return to Index</u>](#index)

------

**15. SEGMENT REPORTING**

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Reservoir Description:* Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients' reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Production Enhancement:* Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

We use the same accounting policies to prepare our operating segment results as are used to prepare our consolidated financial statements. All interest and other non-operating income (expense) is attributable to Corporate & Other and is not allocated to specific operating segments.

Our chief operating decision maker ("CODM") is our Chief Executive Officer, who also serves as Chairman of the Board of Directors. The CODM uses revenue from unaffiliated clients and segment operating income to allocate resources, primarily for working capital, staffing and capital expenditures, during the annual budgeting process and monthly when comparing actual results to budgeted and forecasted results.

Summarized financial information of our operating segments is shown in the following table (in thousands):

[<u>Return to Index</u>](#index)

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Reservoir<br>Description** | **Production<br>Enhancement** | **Corporate &<br>Other** <sup>(1)</sup> | **Consolidated** |
| **Three months ended March 31, 2026** |  |  |  |  |
| CODM Measure - Revenue from unaffiliated clients | $81931 | $39866 | $— | $121797 |
| Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: |
| &nbsp;&nbsp;&nbsp;&nbsp;Inter-segment revenue | 118 | 29 | (147) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services and product sales | 68107 | 33629 | 337 | 102073 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense <sup>(2)</sup> | 9970 | 4748 |  | 14718 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2779 | 985 |  | 3764 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating (income) expense, net <sup>(3)</sup> | (431) | (131) | (463) | (1025) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gain) loss, net <sup>(3)</sup> | 478 | (140) | 42 | 380 |
| &nbsp;&nbsp;&nbsp;&nbsp;CODM Measure - Segment operating income | 1146 | 804 | (63) | 1887 |
| Supplemental Disclosures: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | 333341 | 141142 | 113245 | 587728 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | 4509 | 306 | 76 | 4891 |
| **Three months ended March 31, 2025** |  |  |  |  |
| CODM Measure - Revenue from unaffiliated clients | $80897 | $42688 | $— | $123585 |
| Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: |
| &nbsp;&nbsp;&nbsp;&nbsp;Inter-segment revenue | 16 | 68 | (84) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services and product sales | 64605 | 34761 | 103 | 99469 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense <sup>(2)</sup> | 9038 | 4609 |  | 13647 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2615 | 1102 |  | 3717 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating (income) expense, net <sup>(3)</sup> | 2128 | 539 | (812) | 1855 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gain) loss, net <sup>(3)</sup> | 188 | 242 | 50 | 480 |
| &nbsp;&nbsp;&nbsp;&nbsp;CODM Measure - Segment operating income | 2339 | 1503 | 575 | 4417 |
| Supplemental Disclosures: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets <sup>(4)</sup> | 318436 | 149297 | 118510 | 586243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | 2422 | 1129 | 28 | 3579 |

---

(1) "Corporate & Other" represents those items that are not directly related to a particular operating segment and eliminations.

*(2) General and administrative expense is presented as a total amount to the CODM and consists primarily of employee compensation costs, professional fees and information technology costs.*

*(3) Other operating (income) expense, net and foreign currency exchange (loss), net are included in the consolidated statement of operations as other (income) expense, net. See Note 12 - Other (income) expense, net for further details.* 

*(4) Total assets at March 31, 2025 included in the Reservoir Description operating segment have been adjusted for certain prior period immaterial corrections. See Note 2 - Significant Accounting Policies Update.*

[<u>Return to Index</u>](#index)

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion highlights the current operating environment and summarizes the financial position of Core Laboratories Inc. and its subsidiaries as of March 31, 2026, and should be read in conjunction with (i) the unaudited interim consolidated financial statements and notes thereto included elsewhere in this Quarterly Report and (ii) the audited consolidated financial statements and accompanying notes thereto included in our 2025 Annual Report on Form 10-K for the year ended December 31, 2025.

**General**

Core Laboratories Inc. is a Delaware corporation. It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry. These services and products can enable our clients to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. We make measurements on reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. In addition, we assist clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Core Laboratories Inc. has over 70 offices in more than 50 countries and employs approximately 3,300 people worldwide.

References to "Core Lab", "Core Laboratories", the "Company", "we", "our" and similar phrases are used throughout this Quarterly Report and relate collectively to Core Laboratories Inc. and its consolidated affiliates.

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Reservoir Description:* Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients' reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Production Enhancement:* Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

**Cautionary Statement Regarding Forward-Looking Statements**

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 ("Exchange Act"). Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings "Outlook" and "Liquidity and Capital Resources", and in other parts of this Quarterly Report, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "believe", "expect", "anticipate", "estimate", "continue", or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or

[<u>Return to Index</u>](#index)

------

which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While we believe that these statements are and will be accurate, our actual results and experience may differ materially from the anticipated results or other expectations expressed in our statements due to a variety of risks and uncertainties.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see Part II, "Item 1A - Risk Factors" of this Quarterly Report and "Item 1A - Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025, filed by us with the Securities and Exchange Commission ("SEC").

**Outlook**

Currently, global oil inventories are low relative to historical levels, and with continued supply restrictions from the Organization of the Petroleum Exporting Countries and other oil producing nations ("OPEC+") global supply is expected to be managed and maintained at a level to meet or exceed forecasted growth in oil demand for the next few years. During 2023 and 2024, OPEC+ and its key member, Saudi Arabia, announced several mandatory and voluntary reductions in production. The uncertainty around the impact global trade negotiations may have on global economies combined with OPEC+'s announcement of increased production quotas has also increased the likelihood of a surplus in supply causing global inventory levels of crude oil to rise. In May 2025, OPEC+ began to gradually increase production and unwind voluntary production cuts through September 2026, which in turn could create a surplus in supply and lead to even lower commodity prices.

Recent geopolitical developments, including the escalation of armed conflict in the Middle East, have dramatically shifted the crude oil supply-demand balance. On February 28, 2026 the United States and Israel initiated air strikes against Iranian military targets and leadership. Since then, retaliation by Iran against United States and Israeli interests in the Middle East has been widespread. As of the date of the filing of this Quarterly Report, military activity and hostilities continue to escalate in the Middle East, and the situation throughout the region remains volatile, with the potential for continued escalation into a broader and more sustained regional conflict. While the Company believes the fundamentals for energy-related services remain stable, near-term volatility in commodity prices meaningfully raises the level of uncertainty. The Company is monitoring developments with respect to the ongoing military conflict with Iran, including the impact on global commodity prices and potential shipping and logistics disruptions, which could affect our customers and their activity levels in the region.

The Company believes that activity levels associated with smaller-scale, short-cycle crude oil development projects will be more sensitive to a decrease and/or continued volatility of crude-oil prices. As such, we expect changes in crude oil prices will have a greater impact on drilling and completion activity levels in the U.S. onshore market which could directly affect demand for our well completion services and products. Outside the U.S., large-scale international oil and gas projects are expected to be more resilient to the near-term volatility of crude-oil prices, and the Company anticipates client projects will continue to be executed as planned. Recently, revised IEA field data showed that a steeper natural decline rate may represent a dominant long-term supply risk, where the agency projected a sustained upstream investment of approximately $540 to $570 billion per year is required to prevent disruptive declines and to avoid supply shortages and price volatility.

The ongoing geopolitical conflicts between Russia and Ukraine and between the United States, Israel and Iran, along with associated and expanded sanctions in the United States, the European Union, the United Kingdom and other countries continue to cause disruptions to traditional maritime supply chains and the trading of crude oil and derived products, such as diesel fuel. The effective closure of the Strait of Hormuz with the onset of military conflict in Iran has further exacerbated maritime trade flows of crude oil and derived products. Approximately 20% of global crude oil production passes through the Strait of Hormuz and a substantial portion of that crude oil remains stranded. These disruptions to the trading and maritime transport of crude oil directly impact demand for the Company's associated laboratory assay services. Although demand for the Company's laboratory assay services continued to increase during 2025, geopolitical conflict and associated sanctions continue to create a

[<u>Return to Index</u>](#index)

------

higher level of uncertainty. We have no way to predict the progress or outcome of these events, and any resulting government responses are fluid and beyond our control.

We continue to focus on large-scale core analyses and reservoir fluids characterization studies in most oil-producing regions across the globe, which include both newly developed fields and brownfield extensions in many offshore developments in both the U.S. and internationally. In the U.S. we are involved in projects in many of the onshore unconventional basins and offshore projects in the Gulf of Mexico. Outside the U.S. we continue to work on many smaller and large-scale projects analyzing crude oil and derived products in every major producing region of the world. Notable larger projects are in locations such as Guyana and Suriname located offshore South America, Australia, West Africa and the Middle East. Analysis and measurement of crude oil derived products also occur in every major producing region of the world. Additionally, some of our major clients have increased their investment in projects to capture and sequester carbon dioxide.

Our major clients continue to focus on capital management, return on invested capital, free cash flow, and returning capital to their shareholders, as opposed to a focus on production growth. The companies adopting value versus volume metrics tend to be the more technologically sophisticated operators and form the foundation of Core Lab's worldwide client base. The Company expects our clients' activities associated with increasing oil and gas reserves and production levels will continue to increase in the coming years.

[<u>Return to Index</u>](#index)

------

**Results of Operations**

Our results of operations as a percentage of applicable revenue are as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |
|  | **2026** | **2026** | **2025** | **2025** | **$ Change** | **% Change** |
| REVENUE: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | $94252 | 77% | $95091 | 77% | $(839) | (1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales | 27545 | 23% | 28494 | 23% | (949) | (3)% |
| Total revenue | 121797 | 100% | 123585 | 100% | (1788) | (1)% |
| OPERATING EXPENSES: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services, exclusive of depreciation expense shown below\* | 76115 | 81% | 72980 | 77% | 3135 | 4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product sales, exclusive of depreciation expense shown below\* | 25958 | 94% | 26489 | 93% | (531) | (2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of services and product sales | 102073 | 84% | 99469 | 80% | 2604 | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense, exclusive of depreciation expense shown below | 14718 | 12% | 13647 | 11% | 1071 | 8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3764 | 3% | 3717 | 3% | 47 | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (645) | (1)% | 2335 | 2% | (2980) | NM |
| OPERATING INCOME | 1887 | 2% | 4417 | 4% | (2530) | (57)% |
| Interest expense | 2891 | 2% | 2602 | 2% | 289 | 11% |
| Income (loss) before income taxes | (1004) | (1)% | 1815 | 1% | (2819) | NM |
| Income tax expense (benefit) | (251) | —% | 1746 | 1% | (1997) | NM |
| Net income (loss) | (753) | (1)% | 69 | —% | (822) | NM |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to non-controlling interest | 36 | —% | 223 | —% | (187) | NM |
| Net income (loss) attributable to Core Laboratories Inc. | $(789) | (1)% | $(154) | —% | $(635) | 412% |
| **Other Data:** |  |  |  |  |  |  |
| Current ratio <sup>(1)</sup> | 2.05:1 |  | 2.21:1 |  |  |  |
| Debt to EBITDA ratio <sup>(2)</sup> | 1.34:1 |  | 1.37:1 |  |  |  |
| Debt to Adjusted EBITDA ratio <sup>(3)</sup> | 1.20:1 |  | 1.31:1 |  |  |  |

---

"NM" means not meaningful

\*Percentage based on applicable revenue rather than total revenue

*(1) Current ratio is calculated as follows: current assets divided by current liabilities.*

*(2) Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization and certain non-cash adjustments.*

*(3) Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.*

[<u>Return to Index</u>](#index)

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |  |  |
|  | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **$ Change** | **% Change** |
| REVENUE: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | $94252 | 77% | $106987 | 77% | $(12735) | (12)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales | 27545 | 23% | 31268 | 23% | (3723) | (12)% |
| Total revenue | 121797 | 100% | 138255 | 100% | (16458) | (12)% |
| OPERATING EXPENSES: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services, exclusive of depreciation expense shown below\* | 76115 | 81% | 80277 | 75% | (4162) | (5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product sales, exclusive of depreciation expense shown below\* | 25958 | 94% | 29239 | 94% | (3281) | (11)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of services and product sales | 102073 | 84% | 109516 | 79% | (7443) | (7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense, exclusive of depreciation expense shown below | 14718 | 12% | 10631 | 8% | 4087 | 38% |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3764 | 3% | 3668 | 3% | 96 | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (645) | (1)% | (1392) | (1)% | 747 | (54)% |
| OPERATING INCOME | 1887 | 2% | 15832 | 11% | (13945) | (88)% |
| Interest expense | 2891 | 2% | 2609 | 2% | 282 | 11% |
| Income (loss) before income taxes | (1004) | (1)% | 13223 | 10% | (14227) | NM |
| Income tax expense (benefit) | (251) | —% | 8094 | 6% | (8345) | NM |
| Net income (loss) | (753) | (1)% | 5129 | 4% | (5882) | NM |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to non-controlling interest | 36 | —% | 181 | —% | (145) | NM |
| Net income (loss) attributable to Core Laboratories Inc. | $(789) | (1)% | $4948 | 4% | $(5737) | NM |
| **Other Data:** |  |  |  |  |  |  |
| Current ratio <sup>(1)</sup> | 2.05:1 |  | 2.02:1 |  |  |  |
| Debt to EBITDA ratio <sup>(2)</sup> | 1.34:1 |  | 1.20:1 |  |  |  |
| Debt to Adjusted EBITDA ratio <sup>(3)</sup> | 1.20:1 |  | 1.10:1 |  |  |  |

---

"NM" means not meaningful

\*Percentage based on applicable revenue rather than total revenue

*(1) Current ratio is calculated as follows: current assets divided by current liabilities.*

*(2) Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation and amortization and certain non-cash adjustments.*

*(3) Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.*

[<u>Return to Index</u>](#index)

------

***Operating Results for the Three Months Ended March 31, 2026 compared to the Three Months Ended March 31, 2025 and December 31, 2025*** 

**Service Revenue**

Service revenue is primarily tied to activities associated with the exploration, appraisal, development and production of oil, gas and derived products outside the U.S. For the three months ended March 31, 2026, service revenue was $94.3 million, a decrease of 1% year-over-year and a decrease of 12% sequentially. Year-over-year, revenues decreased primarily due to lower activity levels in the international markets partially offset by increased activity in the U.S. market. Revenue was negatively impacted by the ongoing geopolitical conflicts in the Middle East, Russia and Ukraine, and expanded sanctions previously discussed, which disrupted our client activity, field access and laboratory operations across certain international markets. The supply-chain disruptions, delays and rerouting of crude oil and derived products through the Strait of Hormuz negatively impacted our laboratory assay services and regional studies. Additionally, severe weather across North America, Europe and the Mediterranean region, negatively impacted certain operations and delayed our client activity.

Sequentially, the decrease in service revenue was primarily due to lower demand for laboratory assay services in several international regions. As discussed above, revenue has been impacted by the ongoing geopolitical conflicts, particularly the Middle East, expanded sanctions that have caused disruptions to certain energy infrastructure, such as restricted field access, temporary declines in the trading and maritime transportation of crude oil and derived products, as well as the weather events across several regions discussed above.

**Product Sales Revenue**

Product sales are primarily tied to U.S. onshore drilling and completion activities and product sales to international markets. Product sales to international markets are typically sold and shipped in bulk, and revenue can vary from one quarter to another. For the three months ended March 31, 2026, product sales revenue of $27.5 million decreased 3% year-over-year and 12% sequentially. Year-over-year, the decrease was primarily due to the lower level of U.S. onshore drilling and completion activity and lower bulk shipments to international markets primarily due to delayed product shipments into the region impacted by the geopolitical conflicts discussed above.

Sequentially, the decrease was due to the lower levels of bulk sales in the international markets but partially offset by increased product sales in the U.S.

**Cost of Services, excluding depreciation**

Cost of services was $76.1 million for the three months ended March 31, 2026, an increase of 4% year-over-year and a decrease of 5% sequentially. The year-over-year increase in cost of services was primarily due to 1) higher shipping and insurance costs resulting from the geopolitical conflicts; and 2) an unfavorable effect of exchange rates on costs denominated in foreign currency, such as the Euro and British Pound, resulting from the devaluation of the U.S. dollar during these periods, causing higher employee compensation and certain other operating costs in some international regions.

Sequentially, the decrease in cost of services is primarily due to a decrease in service revenue partially offset by the increase in employee compensation and certain other operating costs discussed above.

Cost of services expressed as a percentage of service revenue was 81% for the three months ended March 31, 2026, compared to 77% for the same period in the prior year and 75% for the prior quarter and was primarily driven by lower revenue during the three months ended March 31, 2026 as client projects have been delayed or cancelled in the Middle East region as a result of the geopolitical conflict which escalated during the three months ended March 31, 2026. Although service revenue declined, the Company still incurred employee compensation and fixed overhead costs which increased cost of services as a percentage of service revenue. In addition, employee compensation and operating costs were higher due to changes in the exchange rates as discussed above.

[<u>Return to Index</u>](#index)

------

**Cost of Product Sales, excluding depreciation**

Cost of product sales was $26.0 million for the three months ended March 31, 2026, a decrease of 2% year-over-year and 11% sequentially. The year-over-year and sequential decrease in cost of product sales were in line with changes in product sales revenue.

Cost of product sales expressed as a percentage of product sales revenue was 94% for the three months ended March 31, 2026, compared to 93% for the same period in the prior year and compared to 94% in the prior quarter. Changes in cost of product sales expressed as a percentage of product sales revenue year over year was affected by absorption of fixed costs on changes in revenue base and continued increase in certain material and logistic costs during the three months ended March 31, 2026.

**General and Administrative Expense, excluding depreciation**

General and administrative ("G&A") expense includes corporate management and centralized administrative services that benefit our operations.

G&A expense for the three months ended March 31, 2026, was $14.7 million, which increased $1.0 million, compared to the same period in 2025. The year-over-year increase was primarily due to higher stock compensation expense recorded in 2026 along with increased outside service costs.

G&A expense for the three months ended March 31, 2026, increased $4.1 million compared to the prior quarter primarily due to the acceleration of stock compensation expense for retirement eligible executives of $3.7 million in 2026.

**Depreciation and Amortization Expense**

Depreciation and amortization expense for the three months ended March 31, 2026, was $3.8 million, an increase of 1% year-over-year and 3% sequentially. The increase in depreciation and amortization expense compared to the prior year period and sequentially is primarily due to business acquisitions in 2025.

**Other (Income) Expense, Net**

The components of other (income) expense, net, are as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Gain on sale of assets | $(1013) | $(6) |
| Results of non-consolidated subsidiaries | 79 | (37) |
| Foreign exchange (gain) loss, net | 380 | 480 |
| Rents and royalties |  | (7) |
| Return on pension assets and other pension costs | (350) | (280) |
| Assets write-down, loss on lease termination and other exit costs | 639 | 707 |
| Severance and other charges |  | 2256 |
| Other, net | (380) | (778) |
| &nbsp;&nbsp;Total other (income) expense, net | $(645) | $2335 |

---

During the three months ended March 31, 2026 and 2025, as a result of our continuous efforts in consolidating and exiting certain facilities in the U.S. and other international locations for operational efficiency, we sold property in Tulsa, Oklahoma for a net gain of $0.9 million. In addition, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease abandonment and other exit costs of $0.6 million and $0.7 million, respectively.

[<u>Return to Index</u>](#index)

------

Foreign exchange (gain) loss, net for the primary currencies in which we operate and those with a material effect for the period presented is summarized in the following table (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| British Pound | $(64) | $(6) |
| Canadian Dollar | 23 | 46 |
| Euro | (70) | 285 |
| Indonesian Rupiah | 50 | 74 |
| Russian Ruble | 97 | (185) |
| Other currencies, net | 344 | 266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gain) loss, net | $380 | $480 |

---

**Interest Expense**

Interest expense for the three months ended March 31, 2026, was $2.9 million and increased $0.3 million or 11% for both year-over-year and sequentially. The year-over-year and sequential increases are primarily due to borrowings of $50.0 million under the delayed draw term loan at higher variable interest rates used to repay the $45.0 million 2021 Senior Notes Series A at a lower fixed rate. Year over year, this was slightly offset by lower average borrowings and lower rates on our revolving credit facility.

**Income Tax Expense (Benefit)** 

The Company recorded an income tax benefit of $(0.3) million for the three months ended March 31, 2026 compared to income tax expense of $1.7 million for the three months ended March 31, 2025. The effective tax rate for the three months ended March 31, 2026 and 2025, was 25.0% and 96.2%, respectively. The effective tax rate for the three months ended March 31, 2026, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter. The effective tax rate for the three months ended March 31, 2025, was impacted by approximately $1.4 million of additional tax expense recorded for items discrete to the quarter. These discrete items are primarily associated with the finalization of certain tax jurisdictions' return to provision assessments due to changes in estimates.

**Segment Analysis**

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. The following tables summarize our results by operating segment (in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Year-Over-Year** | **Sequential** |
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2025** | **March 31, 2025** | **December 31, 2025** | **December 31, 2025** | **% Change** | **% Change** |
| **REVENUE:** |  |  |  |  |  |  |  |  |
| Reservoir Description | $81931 | 67% | $80897 | 65% | $92282 | 67% | 1% | (11)% |
| Production Enhancement | 39866 | 33% | 42688 | 35% | 45973 | 33% | (7)% | (13)% |
| &nbsp;&nbsp;Consolidated | $121797 | 100% | $123585 | 100% | $138255 | 100% | (1)% | (12)% |
| **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** | **OPERATING INCOME:** |
| Reservoir Description \* | $1146 | 1% | $2339 | 3% | $12823 | 14% | (51)% | (91)% |
| Production Enhancement \* | 804 | 2% | 1503 | 4% | 3025 | 7% | (47)% | (73)% |
| Corporate and Other <sup>(1)</sup> | (63) | 0% | 575 | 0% | (16) | 0% | NM | NM |
| &nbsp;&nbsp;Consolidated | $1887 | 2% | $4417 | 4% | $15832 | 11% | (57)% | (88)% |
| *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* | *\* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue.<br>"NM" means not meaningful<br>(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.* |

---

[<u>Return to Index</u>](#index)

------

**Reservoir Description**

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of its revenue sourced from existing producing fields, development projects and movement of crude oil products outside the U.S.

Revenue from the Reservoir Description operating segment of $81.9 million for the three months ended March 31, 2026 increased 1% year-over-year and decreased 11% sequentially. Year-over-year revenue was slightly higher for reservoir rock and fluid analysis projects in the U.S. and laboratory crude assay services in the Europe region. However, sequentially, the recent conflict in the Middle East, coupled with ongoing geopolitical conflict in Russia and Ukraine, and the expanded sanctions previously discussed, further disrupted client activity and demand for our crude assay work and regional studies in certain international regions in the three months ended March 31, 2026.

Operating income of $1.1 million for the three months ended March 31, 2026, decreased year-over-year by $1.2 million and decreased $11.7 million sequentially. Operating margins were 1% for the three months ended March 31, 2026, compared to 3% for the same period in the prior year, and 14% sequentially. Year-over-year, despite a slight increase in revenue, the decrease in operating income and operating margins was primarily attributable to 1) increases in employee compensation and operating costs caused by unfavorable effects of exchange rates discussed above; and 2) a higher level of Corporate G&A expenses of $0.7 million absorbed in the segment. See discussion of *General and Administrative Expense*, above. These cost increases were partially offset by lower facility exit costs and certain asset write-downs totaling $0.6 million recorded during the three months ended March 31, 2026 compared to a total charge of $2.7 million on severance, facility exit costs and asset write-downs recorded for the three months ended March 31, 2025.

Sequentially, the decrease in operating income and operating margins was primarily due to 1) a decrease in revenue of $10.4 million in the three months ended March 31, 2026; 2) a total charge of $0.6 million associated with facility exit costs and certain asset write-downs recorded during the three months ended March 31, 2026 and no such costs recorded in prior quarter; and 3) a higher level of Corporate G&A expenses of $3.3 million absorbed in the segment. See discussion of *General and Administrative Expense*, above.

**Production Enhancement**

Production Enhancement operations are largely focused on complex completions in unconventional oil and gas reservoirs in the U.S. as well as conventional projects across the globe. U.S. onshore drilling and completion activities typically experience a seasonal decline at end of the year with activity levels increasing at the beginning of the year. Average rig count in the U.S. land market for the three months ended March 31, 2026, was down by 7% year-over-year but was relatively flat sequentially. International rig count was down 1% year-over-year but increased by 2% sequentially.

Revenue from the Production Enhancement operating segment of $39.9 million for the three months ended March 31, 2026, decreased 7% year-over-year and 13% sequentially. Year-over-year, the decrease was primarily due to lower product sales due to the decline in bulk shipments in the international market, while the U.S. land market was relatively flat. Sequentially, the decrease was primarily driven by a decrease in large customer bulk shipment orders in the international markets, as well as a decrease in US land market activity.

Operating income of $0.8 million for the three months ended March 31, 2026, decreased $0.7 million year-over-year, and decreased $2.2 million sequentially. Operating margins for the three months ended March 31, 2026, were 2%, compared to operating margins of 4% year-over-year and 7% sequentially. Year-over-year, the decrease in operating income and margins was primarily due to 1) a decrease in revenue of $2.8 million; and 2) continued increase in certain material and logistic costs during the three months ended March 31, 2026.

[<u>Return to Index</u>](#index)

------

Sequentially, the decrease in operating income and margins was primarily driven by 1) a decrease in revenue of $6.1 million for the reasons discussed above; 2) increased materials and operational cost discussed above; and 3) a higher level of Corporate G&A expenses of $1.5 million absorbed in the segment. See discussion of *General and Administrative Expense*, above.

**Liquidity and Capital Resources**

**General**

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, equity financing and the issuance of debt. Cash flows from operating activities provide the primary source of funds to finance operating needs, capital expenditures, dividends and discretionary share repurchases. Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We believe our future cash flows from operations, supplemented by our borrowing capacity and the ability to issue additional equity and debt, should be sufficient to fund our debt requirements, capital expenditures, working capital, dividends, discretionary share repurchases and future acquisitions. The Company will continue to monitor and evaluate the availability of capital in the debt and equity markets.

We are a holding company incorporated in Delaware and we conduct substantially all of our operations through our subsidiaries. Our cash availability is largely dependent upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us and on the terms and conditions of our existing and future credit arrangements. There are no restrictions preventing any of our subsidiaries from repatriating earnings, except for the unrepatriated earnings of our Russian subsidiary which are not expected to be distributed in the foreseeable future, and there are no restrictions or income taxes associated with distributing cash to the parent company through loans or advances.

**Cash Flows**

As of March 31, 2026, we had $22.8 million of cash and cash equivalents, compared to $22.7 million of cash and cash equivalents at December 31, 2025. As of March 31, 2026, $22.1 million of our $22.8 million of cash was held by our foreign subsidiaries.

Cash flows from operating activities were $4.0 million for the three months ended March 31, 2026. The decrease compared to the same period in the prior year was primarily due to lower operating activity and higher operating costs, as discussed above.

Other sources of cash during the three months ended March 31, 2026 include receipt of $1.2 million from the sale of property in Tulsa, Oklahoma. See "Credit Facility, Senior Notes and Available Future Liquidity" below regarding a net increase in our debt of $4.0 million.

Uses of cash during the three months ended March 31, 2026 include: 1) total capital expenditures of $4.9 million, which includes $1.4 million related to the replacement of assets damaged in the Aberdeen, U.K. fire incident which have been covered by insurance proceeds; 2) share repurchases of $4.0 million, which includes payments related to personal tax liabilities of participants in our stock-based compensation plan; and 3) quarterly dividend paid of $0.5 million.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures. Management believes that free cash flow provides useful information to investors regarding the cash available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a

[<u>Return to Index</u>](#index)

------

measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies. The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Free cash flow calculation:** |  |  |
| Net cash provided by operating activities | $3965 | $6660 |
| Less: Cash paid for capital expenditures - operations | (3448) | (2785) |
| &nbsp;&nbsp;&nbsp;&nbsp;Free cash flow | $517 | $3875 |

---

Free cash flow for the three months ended March 31, 2026 was $0.5 million compared to $3.9 million for the same period in 2025. The net cash provided by operating activities of $4.0 million during the three months ended March 31, 2026 compared to $6.7 million for the same period in 2025 was primarily due to the factors as discussed in cash flow from operating activities above. Capital expenditures-operations, which exclude capital expenditures of $1.4 million associated with the Aberdeen, U.K. fire incident that are covered by insurance, increased by $0.7 million during the three months ended March 31, 2026 compared to the same period in the prior year.

**Credit Facility, Senior Notes and Available Future Liquidity**

We, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. ("CLIH"), have a secured credit facility for an aggregate borrowing commitment of $150.0 million with a $50.0 million "accordion" feature ("Credit Facility"). Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million was made in the form of a delayed draw term loan on January 12, 2026. The $50.0 million proceeds from the delayed draw term loan were primarily used to retire $45 million of the senior notes which matured on January 12, 2026, as discussed below. As of March 31, 2026, the Credit Facility has an available borrowing capacity of approximately $85.5 million.

Additionally, we along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions ("Senior Notes"). On January 12, 2026, we repaid the 2021 Senior Notes Series A with aggregate principal amount of $45.0 million upon the maturity date with the single draw of $50.0 million from the delayed draw term loan.

These debt instruments are summarized in the following table (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Interest Rate** | **Maturity Date** | **March 31,<br>2026** | **December 31,<br>2025** |
| Credit Facility - Revolving Loan | Variable | July 22, 2029 | $2000 | $3000 |
| Credit Facility - Delayed Draw Term Loan | Variable | July 22, 2029 | 50000 |  |
| 2021 Senior Notes Series A <sup>(1)</sup> | 4.09% | January 12, 2026 |  | 45000 |
| 2021 Senior Notes Series B <sup>(1)</sup> | 4.38% | January 12, 2028 | 15000 | 15000 |
| 2023 Senior Notes Series A <sup>(2)</sup> | 7.25% | June 28, 2028 | 25000 | 25000 |
| 2023 Senior Notes Series B <sup>(2)</sup> | 7.50% | June 28, 2030 | 25000 | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt |  |  | 117000 | 113000 |
| Less: Debt issuance costs |  |  | (2540) | (2745) |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, net |  |  | $114460 | $110255 |

---

&nbsp;&nbsp;&nbsp;&nbsp;*(1) Interest is payable semi-annually on June 30 and December 30.*

&nbsp;&nbsp;&nbsp;&nbsp;*(2) Interest is payable semi-annually on March 28 and September 28.*

See Note 6 - *Long-term Debt, net* of the Notes to the Interim Consolidated Financial Statements for additional information regarding the terms and financial covenants of the Credit Facility and the Senior Notes.

[<u>Return to Index</u>](#index)

------

In accordance with the terms of the Credit Facility, our leverage ratio is 1.20, and our interest coverage ratio is 7.20, each for the period ended March 31, 2026. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of March 31, 2026. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

See Note 10 - *Derivative Instruments and Hedging Activities* of the Notes to the Interim Consolidated Financial Statements, for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our 2023 Senior Notes Series A and B.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

There have been no material changes in market risk from the information provided in Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" of Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

**Item 4. Controls and Procedures**

A complete discussion of our controls and procedures is included in Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

**Disclosure Controls and Procedures**

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026, at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the fiscal quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

[<u>Return to Index</u>](#index)

------

**CORE LABORATORIES INC.**

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings** 

See Note 8 - *Commitments and Contingencies* of the Notes to the Interim Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report.

**Item 1A. Risk Factors** 

Our business faces many risks. Any of the risks discussed in this Quarterly Report or our other SEC filings could have a material impact on our business, financial position or results of operations.

Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also impair our business operations. For a detailed discussion of the risk factors that should be understood by any investor contemplating investment in our securities, please refer to "Item 1A - Risk Factors" in Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Unregistered Sales of Equity Securities**

None.

**Issuer Purchases of Equity Securities**

The following table provides information about our purchases of shares of our common stock, par value $0.01, that are registered by us pursuant to Section 12 of the Exchange Act during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number** **<br>of Shares<br>Purchased** <sup>(1)</sup> | **Average Price<br>Paid Per<br>Share** | **Total Number of Shares<br>Purchased as Part of a<br>Publicly Announced<br>Program** <sup>(2)</sup> | **Maximum Number of<br>Shares That May Yet be<br>Purchased Under the<br>Program** <sup>(2)</sup> |
| January 1-31, 2026 |  | $— |  |  |
| February 1-28, 2026 | 50216 | $18.08 |  |  |
| March 1-31, 2026 | 1565 | $17.59 |  |  |
| Total | 51781 | $18.06 |  |  |

---

(1)During the three months ended March 31, 2026, we repurchased 50,086 shares in the open market. Additionally, 1,695 shares were surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award. The repurchase of shares in the open market is at the discretion of our Board of Directors and management.

(2)The Company does not have a publicly announced share repurchase program; however, it does from time to time undertake share repurchases in the open market at the discretion of Company management and with prior authorization from the Board of Directors.

**Item 5. Other Information**

During the three months ended March 31, 2026, no director or officer of the Company adopted, modified or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" within the meaning of Item 408(a) of Item 408 of Regulation S-K.

[<u>Return to Index</u>](#index)

------

**Item 6. Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit**<br>**No.** | **Exhibit Title** | **Incorporated by**<br>**reference from the**<br>**following documents** |
| 3.1 | [<u>First Amended and Restated Bylaws</u>](https://www.sec.gov/Archives/edgar/data/1958086/000119312526093962/clb-ex3_1.htm) | Form 8-K, March 5, 2026 |
| 31.1 | [<u>Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](clb-ex31_1.htm) | Filed herewith |
| 31.2 | [<u>Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](clb-ex31_2.htm) | Filed herewith |
| 32.1 | [<u>Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](clb-ex32_1.htm) | Furnished herewith |
| 32.2 | [<u>Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](clb-ex32_2.htm) | Furnished herewith |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | Filed herewith |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | Filed herewith |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | Filed herewith |

---

[<u>Return to Index</u>](#index)

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories Inc., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **CORE LABORATORIES INC.** | **CORE LABORATORIES INC.** |
| Date: | April 30, 2026 | By: | /s/ Christopher S. Hill |
|  |  |  | Christopher S. Hill |
|  |  |  | Chief Financial Officer |
|  |  |  | (Duly Authorized Officer and |
|  |  |  | Principal Financial Officer) |

---

[<u>Return to Index</u>](#index)

------

## Exhibit 31.1

**Exhibit 31.1**

Certification

I, Lawrence V. Bruno, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories Inc. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Lawrence V. Bruno |
|  |  |  | Lawrence V. Bruno |
|  |  |  | Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2**

Certification

I, Christopher S. Hill, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories Inc. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Christopher S. Hill |
|  |  |  | Christopher S. Hill |
|  |  |  | Chief Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1**

Certification of

Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Lawrence V. Bruno, Chief Executive Officer of Core Laboratories Inc. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended March 31, 2026, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | /s/ Lawrence V. Bruno | /s/ Lawrence V. Bruno |
|  |  | Name: | Lawrence V. Bruno |
|  |  | Title: | Chief Executive Officer |

---

------

## Exhibit 32.2

**Exhibit 32.2**

Certification of

Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Christopher S. Hill, Chief Financial Officer of Core Laboratories Inc. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended March 31, 2026, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | /s/ Christopher S. Hill | /s/ Christopher S. Hill |
|  |  | Name: | Christopher S. Hill |
|  |  | Title: | Chief Financial Officer |

---

------